Raab & Moskowitz Asset Management LLC Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Raab & Moskowitz Asset Management LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,447 shares of the biopharmaceutical company’s stock after selling 243 shares during the period. Raab & Moskowitz Asset Management LLC’s holdings in Gilead Sciences were worth $360,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in GILD. Tompkins Financial Corp boosted its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. OFI Invest Asset Management purchased a new stake in Gilead Sciences during the 3rd quarter valued at $26,000. Fortitude Family Office LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Rakuten Securities Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $33,000. Finally, Financial Connections Group Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.2 %

NASDAQ:GILD traded up $0.15 on Friday, reaching $65.42. 12,382,425 shares of the stock traded hands, compared to its average volume of 6,443,315. The company has a market capitalization of $81.45 billion, a price-to-earnings ratio of 181.72, a PEG ratio of 1.17 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12 month low of $64.63 and a 12 month high of $87.86. The company’s fifty day simple moving average is $71.28 and its 200 day simple moving average is $76.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business earned $1.37 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 4.2 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.71%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s payout ratio is presently 855.56%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several analyst reports. Mizuho dropped their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. UBS Group dropped their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Royal Bank of Canada dropped their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research report on Friday. Finally, HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price for the company in a research report on Wednesday. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and an average price target of $83.87.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.